Exploring the Interplay Between Chronic Kidney Disease and Cardiovascular Disease
HCPLive
OCTOBER 31, 2024
In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.
Kidney Disease Related Topics 
Kidney Compass: Semaglutide for Nondiabetic Kidney Disease, with Hiddo Heerspink, PhD, PharmD, at Kidney Week 2024
HCPLive
OCTOBER 27, 2024
Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.
Kidney Disease 
133
133 
ASN Releases New Guidance on Obesity Management in Kidney Disease
HCPLive
SEPTEMBER 18, 2024
The new guidance reviews existing tools for weight management and provides recommendations for their use in clinical practice in patients with obesity and kidney disease.
Kidney Disease 104
104 
Moving Beyond the Joint: The Interplay Between Gout and Kidney Disease
HCPLive
SEPTEMBER 20, 2024
Nehad Soloman, MD, FACR; Andrew Sharobeem, DO, FACR, and Sunil Patel, MD, explore the nephrologist's vital role in gout diagnosis, treatment options for gout patients with chronic kidney disease, and strategies for managing refractory gout and its associated challenges.
Kidney Disease 105
105 Kidney Disease 105
105 
FLOW Trial Fortifies Semaglutide's Role in Chronic Kidney Disease and Type 2 Diabetes
HCPLive
MAY 24, 2024
mg reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease, according to the FLOW trial. Semaglutide 1.0
Kidney Disease 116
116 
Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial
Cardiovascular Diabetology
AUGUST 23, 2024
Diabetic kidney disease (DKD) is associated with a higher risk of cardiovascular disease (CVD). Pentoxifylline (PTF), a nonselective phosphodiesterase inhibitor with anti-inflammatory, antiproliferative, and a.
Kidney Disease 129
129 
Diagnosis of Crohn’s Disease Linked to Chronic Kidney Disease Risk
HCPLive
MAY 18, 2024
A diagnosis of chronic kidney disease was approximately 3-times more likely in Crohn's disease than in ulcerative colitis.
Kidney Disease 111
111 Kidney Disease 111
111 
Obesity Associated With Renal Function Decline, Kidney Disease Risk
HCPLive
FEBRUARY 2, 2024
Obesity was linked to an increased risk of focal segmental glomerulosclerosis and hypertensive nephropathy, with further analysis revealing its impact on the risk of developing end-stage kidney disease.
Kidney Disease 105
105 
Quantifying variant contributions in cystic kidney disease using national-scale whole-genome sequencing
Journal of Clinical Investigation - Cardiology
OCTOBER 1, 2024
of cases, a qualifying potentially disease-causing rare variant in an established gene was found.
Kidney Disease 119
119 
IgAN, Kidney Disease Common Among Patients with Inflammatory Bowel Disease
HCPLive
JANUARY 23, 2024
Findings from the retrospective cohort study suggest an increased prevalence of advanced kidney disease among individuals with Crohn disease and ulcerative colitis.
Kidney Disease 105
105 Kidney Disease 105
105 
Clinical Quiz: Protein and Energy Intake in Chronic Kidney Disease from KDOQI Guidelines
HCPLive
MAY 17, 2024
Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for protein and energy intake!
Kidney Disease 104
104 Kidney Disease 104
104 
International Consensus Statement Calls for Prioritization of Kidney Disease by the WHO
HCPLive
APRIL 17, 2024
The consensus calls for the recognition of kidney disease as a major non-communicable disease driver of premature mortality by the World Health Organization.
APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease
Journal of Clinical Investigation - Cardiology
MARCH 1, 2024
Two coding variants of apolipoprotein L1 (APOL1), called G1 and G2, explain much of the excess risk of kidney disease in African Americans. While various cytotoxic phenotypes have been reported in experimental models, the proximal mechanism by which G1 and G2 cause kidney disease is poorly understood.
Kidney Disease 102
102 Kidney Disease 102
102 
Empagliflozin Benefits on Kidney Disease Progression, Death Continue for 1 Year Post-Discontinuation
HCPLive
OCTOBER 25, 2024
After discontinuing therapy, treated participants still had an overall 13% reduction in the risk of kidney disease progression or cardiovascular death.
Gut Microbiota Dysbiosis Significantly Influences Chronic Kidney Disease Progression
HCPLive
DECEMBER 14, 2023
Microbiota-based interventions may be a novel strategy to benefit the mitigation of chronic kidney disease advancement.
In Acute Kidney Disease, SGLT2 inhibitors Were All-Around Protective
Med Page Today
JANUARY 4, 2024
(MedPage Today) -- SGLT2 inhibitors significantly lowered the risk of death, major adverse kidney events (MAKE), and major adverse cardiovascular events (MACE) in people with type 2 diabetes and acute kidney disease, according to a cohort study.
Kidney Disease 105
105 
Adults younger than 40 with ideal heart health had lower heart disease, stroke, and kidney disease risk
American Heart News - Heart News
MARCH 21, 2024
Research Highlights: A study of nearly 4 million young adults under age 40 in South Korea found that those who had ideal cardiovascular health were nearly two-thirds less likely to develop heart disease, stroke and/or kidney disease during a 12-year.
Kidney Disease 105
105 
SGLT-2is Mitigate Risk of Cardiovascular, Kidney Diseases in Patients with Type 2 Diabetes and AKD
HCPLive
JANUARY 4, 2024
Compared to nonusers, patients with type 2 diabetes and acute kidney disease administered SGLT-2is had a significantly lower risk of mortality, major adverse kidney events, and major adverse cardiovascular events.
Kidney Disease 104
104 
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease
The New England Journal of Medicine
OCTOBER 24, 2024
Two years of empagliflozin slowed kidney disease progression or cardiovascular death. In this post-trial study, empagliflozin had additional cardiorenal benefits after discontinuation.
Targeting de novo lipogenesis to mitigate kidney disease
Journal of Clinical Investigation - Cardiology
FEBRUARY 15, 2024
Ten percent of the population worldwide suffers from chronic kidney disease (CKD), but the mechanisms driving CKD pathology are incompletely understood. Identify acyl-CoA synthetase short-chain family 2 (ACSS2) as a disease risk gene and demonstrate a role for ACSS2 in de novo lipogenesis (DNL).
ACSS2 gene variants determine kidney disease risk by controlling de novo lipogenesis in kidney tubules
Journal of Clinical Investigation - Cardiology
FEBRUARY 15, 2024
Worldwide, over 800 million people are affected by kidney disease, yet its pathogenesis remains elusive, hindering the development of novel therapeutics. Lipid accumulation and the expression of genes related to DNL were elevated in the kidneys of patients with fibrosis.
Heart failure causally linked to chronic kidney disease
Medical Xpress - Cardiology
DECEMBER 19, 2023
Heart failure is causally associated with chronic kidney disease (CKD), according to a study published online Dec. 11 in PLOS ONE.
People With Psoriatic Arthritis at Risk For Chronic Kidney Disease
HCPLive
NOVEMBER 13, 2024
People with diabetes, kidney stones, damaged joints, high uric acids, and daily use of NSAID were more likely to develop CKD than others.
Kidney Disease 102
102 
External validation and calibration of risk equations for prediction of diabetic kidney diseases among patients with type 2 diabetes in Taiwan
Cardiovascular Diabetology
OCTOBER 8, 2024
Most existing risk equations for predicting/stratifying individual diabetic kidney disease (DKD) risks were developed using relatively dated data from selective and homogeneous trial populations comprising pre.
Depagliflozin Lowers Risk of Decline in Late-Stage Kidney Disease
HCPLive
OCTOBER 26, 2024
The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.
Kidney Disease 111
111 Kidney Disease 111
111 
Adeno-associated virus–based gene therapy treats inflammatory kidney disease in mice
Journal of Clinical Investigation - Cardiology
SEPTEMBER 3, 2024
The development of AAV2-GEC and its successful application in the treatment of antibody-mediated kidney disease represents a significant step forward and opens up promising avenues for kidney medicine. Taken together, this study showcases the potential of AAV as a gene delivery platform for challenging cell types.
Abdul Abdellatif, MD: Early Osteopenia Interventions Needed for Patients With Kidney Disease and Gout
HCPLive
OCTOBER 28, 2024
Abdellatif discussed the importance of screening for osteopenia in patients with severe kidney disease.
Urinary Prostaglandin E2 Excretion and the Risk of Cardiovascular and Kidney Disease
Journal of the American Heart Association
FEBRUARY 16, 2024
BackgroundInhibition of prostaglandin synthesis by nonsteroidal anti‐inflammatory drugs is associated with cardiovascular mortality and kidney disease. Future studies should address whether these associations are causal and can be targeted to improve cardiovascular and kidney outcomes.
Prognostic impact of switching to the 2021 chronic kidney disease epidemiology collaboration creatinine-based equation in Caucasian patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular events (RIACE) Italian Multicenter Study
Cardiovascular Diabetology
OCTOBER 23, 2024
A Chronic Kidney Disease (CKD) Epidemiology Collaboration (EPI) formula not including a Black race coefficient has been recently developed and is now recommended in the US. The new (2021) equation was shown to.
Incidence and Outcomes of Cardiovascular Implantable Electronic Device Infections in Patients with End-Stage Kidney Disease
HeartRhythm
SEPTEMBER 11, 2024
End-stage kidney disease (ESKD) patients are prone to bloodstream infections which may result in a higher risk of cardiac implantable electronic device (CIED) infections.
Association of Chronic Kidney Disease and Kidney Failure with Replacement Therapy with Procedural and Long-Term Outcomes after First Generation Watchman Device: Insights from the NCDR LAAO Registry
HeartRhythm
NOVEMBER 5, 2024
Chronic kidney disease (CKD) and kidney failure with replacement therapy (KFRT) are prevalent in patients with atrial fibrillation (AF).
Frail hypertensive older adults with prediabetes and chronic kidney disease: insights on organ damage and cognitive performance - preliminary results from the CARYATID study
Cardiovascular Diabetology
APRIL 9, 2024
Hypertension and chronic kidney disease (CKD) pose significant public health challenges, sharing intertwined pathophysiological mechanisms. Prediabetes is recognized as a precursor to diabetes and is often acc.
Incident heart failure and the subsequent risk of progression to end stage kidney disease in individuals with type 2 diabetes
Cardiovascular Diabetology
JUNE 14, 2024
Diabetic kidney disease is an established risk factor for heart failure. However, the impact of incident heart failure on the subsequent risk of renal failure has not been systematically assessed in diabetic p.
Endothelin System in Hypertension and Chronic Kidney Disease
Hypertension Journal
DECEMBER 7, 2023
ETs were shown to play important roles among others, in systemic hypertension, particularly when resistant or difficult to control, and in pulmonary hypertension, atherosclerosis, cardiac hypertrophy, subarachnoid hemorrhage, chronic kidney disease, diabetic cardiovascular disease, scleroderma, some cancers, etc.
Abstract 4145373: PREVALENCE OF NON-RHEUMATIC MITRAL STENOSIS IN CHRONIC KIDNEY DISEASE: NATIONAL IN-PATIENT SAMPLE ANALYSIS
Circulation
NOVEMBER 11, 2024
Background:There have been several studies postulating the association between Mitral valve stenosis (MS) and Chronic Kidney Disease (CKD). Circulation, Volume 150, Issue Suppl_1 , Page A4145373-A4145373, November 12, 2024.
FDA Accepts sNDA for Furosemide (Furoscix) in Chronic Kidney Disease
HCPLive
JULY 25, 2024
The sNDA for furosemide seeks to expand the indication to include the treatment of edema due to fluid overload in patients with CKD, with a PDUFA date of March 6, 2025.
Kidney Disease 109
109 Kidney Disease 109
109 
Kidney disease linked to increased mortality after stroke thrombolysis
Medical Xpress - Cardiology
DECEMBER 13, 2023
Renal dysfunction, especially chronic kidney disease, is the biggest risk factor of mortality among thrombolysed stroke patients, according to a retrospective cohort observational study published in Medicine.
Empowering Patients with Educational Resources for Kidney Disease, with Mike Spigler
HCPLive
JULY 23, 2024
Spigler provides insight into the development of new patient-focused guidelines for managing hyperkalemia in CKD and the importance of providing patients with such resources.
Kidney Disease 111
111 Abstract 4142036: Association of smoking status with incident heart failure among patients with chronic kidney disease: Insights from CRIC
Circulation
NOVEMBER 11, 2024
Introduction:Smoking is a well-known risk factor for atherosclerotic cardiovascular disease and kidney failure among patients with chronic kidney disease (CKD). Circulation, Volume 150, Issue Suppl_1 , Page A4142036-A4142036, November 12, 2024. However, the association of former and current smoking status (vs.
Semaglutide Shows Promise, Reduces UACR in Nondiabetic Kidney Disease
HCPLive
OCTOBER 25, 2024
New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.
Efficacy and Safety of Aldosterone Synthase Inhibition With and Without Empagliflozin for Chronic Kidney Disease
American College of Cardiology
JANUARY 11, 2024
The goal of the ASi in CKD trial was to determine the effect on albuminuria of BI 690517, an investigational aldosterone synthase inhibitor, alone and in combination with empagliflozin compared with placebo in patients with chronic kidney disease (CKD).
Higher inpatient mortality following percutaneous coronary intervention in patients with advanced chronic kidney disease
Coronary Artery Disease Journal
JUNE 18, 2024
Background Advanced chronic kidney disease (ACKD) is common in patients undergoing percutaneous coronary intervention (PCI) and is associated with adverse outcomes. These patients are often excluded from revascularization studies. The goal of this study was to evaluate the impact of ACKD in patients undergoing PCI.
Association of long-term triglyceride-glucose index patterns with the incidence of chronic kidney disease among non-diabetic population: evidence from a functional community cohort
Cardiovascular Diabetology
JANUARY 2, 2024
The triglyceride-glucose (TyG) index is a reliable surrogate marker of insulin resistance and previous studies have confirmed the association of TyG index with incident chronic kidney disease (CKD). However, t.
Anemia Increases Risk of End-Stage Kidney Disease in IgA Nephropathy
HCPLive
MAY 27, 2024
An analysis of more than 800 IgAN patients treated from 2002-2021 provides an overview of factors associated with anmeia as well as its impact on pgronosis.
Kidney Disease 111
111 Kidney Disease 111
111 
Let's personalize your content